Equities Analysts Issue Forecasts for COGT FY2025 Earnings

Cogent Biosciences, Inc. (NASDAQ:COGT) – Equities researchers at Wedbush dropped their FY2025 EPS estimates for shares of Cogent Biosciences in a note issued to investors on Monday, November 10th. Wedbush analyst D. Nierengarten now expects that the technology company will post earnings per share of ($2.02) for the year, down from their prior forecast of ($1.99). Wedbush currently has a “Outperform” rating and a $38.00 target price on the stock. The consensus estimate for Cogent Biosciences’ current full-year earnings is ($2.42) per share. Wedbush also issued estimates for Cogent Biosciences’ Q4 2025 earnings at ($0.45) EPS, FY2027 earnings at ($0.49) EPS and FY2028 earnings at $2.02 EPS.

COGT has been the topic of a number of other research reports. Stifel Nicolaus upgraded Cogent Biosciences from a “hold” rating to a “buy” rating and set a $40.00 price target on the stock in a research report on Monday. Guggenheim increased their target price on Cogent Biosciences from $17.00 to $20.00 and gave the company a “buy” rating in a research report on Monday, August 25th. Weiss Ratings reissued a “sell (e+)” rating on shares of Cogent Biosciences in a research note on Wednesday, October 8th. JPMorgan Chase & Co. upped their price objective on shares of Cogent Biosciences from $30.00 to $44.00 and gave the stock an “overweight” rating in a research report on Tuesday, October 21st. Finally, Robert W. Baird lifted their target price on shares of Cogent Biosciences from $14.00 to $34.00 and gave the company a “neutral” rating in a research report on Tuesday. Two research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Cogent Biosciences currently has an average rating of “Moderate Buy” and an average target price of $29.92.

Cogent Biosciences Trading Up 3.0%

COGT stock opened at $33.42 on Wednesday. Cogent Biosciences has a 52-week low of $3.72 and a 52-week high of $36.15. The company has a quick ratio of 4.19, a current ratio of 6.38 and a debt-to-equity ratio of 0.23. The firm has a market cap of $4.76 billion, a P/E ratio of -20.38 and a beta of 0.41. The company’s 50-day simple moving average is $15.23 and its 200-day simple moving average is $10.93.

Cogent Biosciences (NASDAQ:COGT) last announced its quarterly earnings results on Friday, November 7th. The technology company reported ($0.50) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.04.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in COGT. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Cogent Biosciences by 22.8% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,401 shares of the technology company’s stock valued at $78,000 after purchasing an additional 1,003 shares during the last quarter. ProShare Advisors LLC raised its holdings in shares of Cogent Biosciences by 4.1% during the 2nd quarter. ProShare Advisors LLC now owns 26,021 shares of the technology company’s stock worth $187,000 after acquiring an additional 1,020 shares during the period. Corton Capital Inc. boosted its position in shares of Cogent Biosciences by 6.4% during the 2nd quarter. Corton Capital Inc. now owns 17,438 shares of the technology company’s stock valued at $125,000 after acquiring an additional 1,046 shares during the last quarter. CWM LLC increased its position in Cogent Biosciences by 25.3% during the third quarter. CWM LLC now owns 5,582 shares of the technology company’s stock worth $80,000 after purchasing an additional 1,126 shares during the last quarter. Finally, Osaic Holdings Inc. raised its stake in Cogent Biosciences by 41.4% during the second quarter. Osaic Holdings Inc. now owns 4,550 shares of the technology company’s stock worth $33,000 after purchasing an additional 1,333 shares during the period.

Cogent Biosciences Company Profile

Cogent Biosciences, Inc, a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors.